H R Black

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. ncbi request reprint Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial
    Henry R Black
    Rush Medical College of Rush University, Chicago, IL 60612, USA
    JAMA 289:2073-82. 2003
  2. ncbi request reprint The burden of cardiovascular disease: following the link from hypertension to myocardial infarction and heart failure
    Henry R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 West Van Buren, Suite 470, Chicago, IL 60612, USA
    Am J Hypertens 16:4S-6S. 2003
  3. ncbi request reprint Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region
    Henry R Black
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    J Hypertens 23:1099-106. 2005
  4. ncbi request reprint One-year study of felodipine or placebo for stage 1 isolated systolic hypertension
    H R Black
    Department of Preventive Medicine, Rush Medical College of Rush University at Rush Presbyterian Saint Luke s Medical Center, Chicago, Illinois, USA
    Hypertension 38:1118-23. 2001
  5. ncbi request reprint Isolated systolic hypertension in the elderly: lessons from clinical trials and future directions
    H R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago IL 60612, USA
    J Hypertens Suppl 17:S49-54. 1999
  6. ncbi request reprint Will better-tolerated antihypertensive agents improve blood pressure control? JNC VI revisited
    H R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 12:225S-230S. 1999
  7. ncbi request reprint Controlled-release doxazosin as combination therapy in hypertension: the GATES study
    Henry R Black
    Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 8:159-66; quiz 167-8. 2006
  8. doi request reprint Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Lancet 375:1173-81. 2010
  9. ncbi request reprint The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study
    H R Black
    Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 13:468-74. 2000
  10. ncbi request reprint Optimal blood pressure: how low should we go?
    H R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush Medical College of Rush University, Chicago, Illinois 60612, USA
    Am J Hypertens 12:113S-120S. 1999

Research Grants

Collaborators

Detail Information

Publications78

  1. ncbi request reprint Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial
    Henry R Black
    Rush Medical College of Rush University, Chicago, IL 60612, USA
    JAMA 289:2073-82. 2003
    ..Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial...
  2. ncbi request reprint The burden of cardiovascular disease: following the link from hypertension to myocardial infarction and heart failure
    Henry R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 West Van Buren, Suite 470, Chicago, IL 60612, USA
    Am J Hypertens 16:4S-6S. 2003
    ..Aggressive lowering of BP is critical to help reduce the risk of CVD and help prevent the development of HF...
  3. ncbi request reprint Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region
    Henry R Black
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    J Hypertens 23:1099-106. 2005
    ..To examine regional differences in the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial...
  4. ncbi request reprint One-year study of felodipine or placebo for stage 1 isolated systolic hypertension
    H R Black
    Department of Preventive Medicine, Rush Medical College of Rush University at Rush Presbyterian Saint Luke s Medical Center, Chicago, Illinois, USA
    Hypertension 38:1118-23. 2001
    ..Larger and longer studies will be needed to document any long-term reduction in cardiovascular event rates associated with treating stage 1 systolic hypertension...
  5. ncbi request reprint Isolated systolic hypertension in the elderly: lessons from clinical trials and future directions
    H R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago IL 60612, USA
    J Hypertens Suppl 17:S49-54. 1999
    ..We must also encourage the development of antihypertensive drugs that lower SBP more effectively than those that are currently available...
  6. ncbi request reprint Will better-tolerated antihypertensive agents improve blood pressure control? JNC VI revisited
    H R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 12:225S-230S. 1999
    ....
  7. ncbi request reprint Controlled-release doxazosin as combination therapy in hypertension: the GATES study
    Henry R Black
    Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 8:159-66; quiz 167-8. 2006
    ..0%), the frequency of adverse events was similar for doxazosin GITS and placebo. Doxazosin GITS was effective as combination antihypertensive therapy with the major classes of antihypertensive agents...
  8. doi request reprint Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Lancet 375:1173-81. 2010
    ..We assessed the effects of these drug combinations on progression of chronic kidney disease...
  9. ncbi request reprint The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study
    H R Black
    Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 13:468-74. 2000
    ..These findings demonstrate that doxazosin add-on therapy is an effective, well-tolerated treatment strategy for patients with inadequately controlled hypertension...
  10. ncbi request reprint Optimal blood pressure: how low should we go?
    H R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush Medical College of Rush University, Chicago, Illinois 60612, USA
    Am J Hypertens 12:113S-120S. 1999
    ..Setting appropriate blood pressure goals and working to meet them through aggressive antihypertensive treatment, with multiple agents if necessary, can reduce those risks...
  11. ncbi request reprint Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials
    Henry R Black
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Clin Cornerstone 6:53-66. 2004
    ....
  12. ncbi request reprint Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension
    Henry R Black
    Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612 3824, USA
    J Cardiovasc Pharmacol 41:866-9. 2003
    ..The positive effects of doxazosin on serum lipids make combination therapy with doxazosin an attractive treatment option for patients who have concomitant hyperlipidemia or glucose intolerance...
  13. ncbi request reprint Exercise capacity and the risk of death in women: the St James Women Take Heart Project
    Martha Gulati
    Department of Preventive Medicine, Rush Heart Institute, Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Ave, Suite 020, Chicago, Ill 60612, USA
    Circulation 108:1554-9. 2003
    ..The hypothesis that reduced exercise capacity is associated with an increased risk of death was investigated in a cohort of 5721 asymptomatic women who underwent baseline examinations in 1992...
  14. ncbi request reprint A comparison of two sphygmomanometers that may replace the traditional mercury column in the healthcare workplace
    William J Elliott
    Department of Preventive Medicine, Rush Medical College, Chicago, IL 60612, USA
    Blood Press Monit 12:23-8. 2007
    ....
  15. ncbi request reprint Management of older hypertensive patients: is there a difference in approach?
    Henry R Black
    Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 5:11-6. 2003
    ..No older person should suffer a preventable, life-threatening event or become confined to a wheel chair if attention to lifestyle issues and a few pills a day could avoid that outcome...
  16. ncbi request reprint Prehypertension
    William J Elliott
    Department of Preventive Medicine, Rush Medical College, Rush University Medical Center, Chicago, IL 60612, USA
    Nat Clin Pract Cardiovasc Med 4:538-48. 2007
    ..In this Review, we attempt to summarize the recently published data concerning the epidemiology, attendant risks and potential treatment options for this important and growing public-health problem...
  17. ncbi request reprint Graded blood pressure reduction in hypertensive outpatients associated with use of a device to assist with slow breathing
    William J Elliot
    Department of Preventive Medicine, Rush Medical College of Rush University, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 6:553-9; quiz 560-1. 2004
    ..Thus, even without training, hypertensive patients who receive a device to guide slow breathing significantly lowered their office SBP if the total time spent in slow breathing over 8 weeks exceeded a "threshold" value of 180 minutes...
  18. ncbi request reprint Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data
    Henry R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Am Heart J 147:564-72. 2004
    ..This article reviews the role of the RAAS in the development of hypertension and discusses the rationale for the use of eplerenone with other medications affecting the RAAS to control blood pressure...
  19. ncbi request reprint Treatment of hypertension in the elderly
    Warren J Elliott
    Department of Preventive Medicine, RUSH Medical College of RUSH University at RUSH Presbyterian St Luke s Medical Center, 1700 West Van Buren Street, Chicago, IL 60612, USA
    Am J Geriatr Cardiol 11:11-20; quiz 20-2. 2002
    ..Future cardiovascular risk may be related directly to the blood pressure attained, rather than to how it was attained...
  20. ncbi request reprint Risk stratification of older patients
    Henry R Black
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 15:77S-81S. 2002
    ..Otherwise, a multidrug regimen is constructed and additional agents added in logical fashion. A majority of patients with higher risk can attain control at the specified BP goal safely and effectively by using a combination of agents...
  21. doi request reprint ASH position paper: treatment of hypertension in patients with diabetes-an update
    George L Bakris
    Hypertensive Diseases and Diabetes Center, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:707-13; discussion 714-5. 2008
    ..Last, an updated algorithm is provided that incorporates many of the new findings and is suggested as a starting point to achieve blood pressure goals...
  22. ncbi request reprint The coronary artery disease paradox
    H R Black
    Rush-Presbyterian-St. Luke's Medical Center, Rush Medical College, Chicago, Illinois, USA
    Am J Hypertens 9:2S-10S. 1996
    ..This paper will review these possible reasons for the coronary artery disease paradox, concentrating on classification and problems with drug therapy...
  23. ncbi request reprint Goal-oriented hypertension management: translating clinical trials to practice
    Gregory M Singer
    Rush University Hypertension Service, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    Hypertension 40:464-9. 2002
    ..Although DBP control was easy to achieve, achieving SBP goal still remained difficult. Employing goal-oriented management can translate BP control results achieved in clinical trials into outpatient practice...
  24. ncbi request reprint Prognostic value of the duke treadmill score in asymptomatic women
    Martha Gulati
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 96:369-75. 2005
    ..The role of ST-segment changes and symptoms with stress testing in asymptomatic women does not provide additional prognostic information...
  25. ncbi request reprint The prognostic value of a nomogram for exercise capacity in women
    Martha Gulati
    Department of Preventive Medicine, Rush University Medical Center, Chicago, USA
    N Engl J Med 353:468-75. 2005
    ..Our objectives were to construct a nomogram to permit determination of predicted exercise capacity for age in women and to assess the predictive value of the nomogram with respect to survival...
  26. ncbi request reprint Expanding the definition of hypertension to incorporate global cardiovascular risk
    Nitin Khosla
    Rush University Hypertension Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 8:384-90. 2006
    ..To change this alarming trend, physicians must become aggressive in using the available armamentarium of lifestyle modifications and drugs in treating hypertension and other risk factors that increase the burden of atherosclerosis...
  27. ncbi request reprint Hypertension in women: the Women Take Heart project
    A lice A Furumoto-Dawson
    Department of Preventive Medicine, Rush Medical College, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 5:38-46. 2003
    ..1% of self-reported hypertensives. Results from this study and national surveys indicate that hypertension detection and control remain major public health challenges in preventing cardiovascular disease in older women...
  28. ncbi request reprint Resistant hypertension revisited: a comparison of two university-based cohorts
    Jay P Garg
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois, 60612, USA
    Am J Hypertens 18:619-26. 2005
    ..To assess whether the reasons for and treatment of RH have changed, we determined the frequency of various causes of resistance, the proportion of patients achieving goal BP, and the changes made in antihypertensive regimens...
  29. ncbi request reprint Number needed to treat: solid science or a path to pernicious rationing?
    H R Black
    Rush Presbyterian St Luke s Medical Center, Rush Medical College, Chicago, Illinois, USA
    Am J Hypertens 11:128S-134S; discussion 135S-137S. 1998
    ..We need to be sure that future trials of chronic conditions such as hypertension are done with this trial paradigm, so that those who pay for care have the accurate knowledge needed to spend their money wisely...
  30. ncbi request reprint Antihypertensive therapy and cardiovascular disease. Impact of effective therapy on disease progression
    H R Black
    Department of Preventive Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612-3824, USA
    Am J Hypertens 11:3S-8S. 1998
    ..This article reviews the impact of antihypertensive treatment on cardiovascular disease and treatment endpoints...
  31. ncbi request reprint Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action
    G Bakris
    Department of Medicine, Hypertensive Diseases Center, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    J Hum Hypertens 22:63-70. 2008
    ..These actions should be pursued with vigour in accordance with current clinical guidelines, with the details of implementation adapted to the economic and cultural setting...
  32. ncbi request reprint The paradigm has shifted to systolic blood pressure
    H R Black
    Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    J Hum Hypertens 18:S3-7. 2004
    ....
  33. doi request reprint Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial
    George L Bakris
    University of Chicago, Department of Medicine, Hypertensive Disease Unit, Chicago, Ill, USA
    Hypertension 56:824-30. 2010
    ..The results of this trial highlight the importance of ambulatory BP monitoring in the design of hypertension clinical studies...
  34. doi request reprint Heart rate response to exercise stress testing in asymptomatic women: the st. James women take heart project
    Martha Gulati
    Department of Medicine Cardiology and Preventive Medicine, Northwestern University, Chicago, Ill 60611, USA
    Circulation 122:130-7. 2010
    ..We investigated the association between HR response to exercise testing and age with prognosis in 5437 asymptomatic women...
  35. pmc Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project
    Martha Gulati
    Department of Medicine and Preventive Medicine, Northwestern University, 201 E Huron, Chicago, IL 60611, USA
    Arch Intern Med 169:843-50. 2009
    ..Women with clinical findings suggestive of ischemia but without findings of obstructive coronary artery disease (CAD) on angiography represent a frequent clinical problem; predicting prognosis is challenging...
  36. ncbi request reprint Improving blood pressure control rates: is there more we can do?
    George L Bakris
    Hypertension Center, Endocrine Division, The University of Chicago School of Medicine, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 9:134-42. 2007
  37. ncbi request reprint Guidelines for hypertension: are quality-assurance measures on target?
    Gregory M Singer
    Rush University Hypertension Service, Chicago, Ill, USA
    Hypertension 43:198-202. 2004
    ..Goal-oriented strategy, especially in diabetic subjects, should be aggressively sought rather than relaxing goals to promote achievement...
  38. pmc Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment
    Michael L Maitland
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 15:6250-7. 2009
    ..This prospective, single-center, cohort study characterized ambulatory blood pressure monitoring as an early pharmacodynamic biomarker of VEGF signaling pathway inhibition by sorafenib...
  39. ncbi request reprint Prehypertension and cardiovascular disease risk in the Women's Health Initiative
    Judith Hsia
    Department of Medicine, George Washington University, 2150 Pennsylvania Ave NW, Washington, DC 20037, USA
    Circulation 115:855-60. 2007
    ..Prehypertension is common and is associated with increased vascular mortality. The extent to which it increases risk of nonfatal myocardial infarction, stroke, and congestive heart failure is less clear...
  40. ncbi request reprint Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
    Curr Hypertens Rep 10:330-5. 2008
    ..The most recently introduced drugs, the vasodilating beta-blockers carvedilol and nebivolol, are now being broadly evaluated as to their efficacy and tolerability in clinical practice...
  41. ncbi request reprint The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis
    Paula T Einhorn
    National Heart, Lung, and Blood Institute, Division of Epidemiology and Clinical Applications, Bethesda, MD 20892 7936, USA
    Am Heart J 153:42-53. 2007
    ..However, questions have been raised regarding the validity of the HF diagnosis...
  42. ncbi request reprint Prehypertension--what is it and should it be treated?
    Marvin Moser
    J Clin Hypertens (Greenwich) 8:812-8. 2006
  43. ncbi request reprint Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent
    Henry R Black
    New York University School of Medicine, New York, New York, USA
    Diabetes Care 31:353-60. 2008
    ..Optimal initial antihypertensive drug therapy in people with the metabolic syndrome is unknown...
  44. ncbi request reprint Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  45. ncbi request reprint Microalbuminuria, chronic renal disease, and the effects of the metabolic syndrome on cardiovascular events
    Marvin Moser
    J Clin Hypertens (Greenwich) 9:551-6. 2007
    ..The authors maintained full control of the discussion and the resulting content of this article; Novartis had no input in the choice of topic, speakers, or content...
  46. ncbi request reprint The editor's roundtable: revisiting the role of beta blockers in hypertension
    William C Roberts
    Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA
    Am J Cardiol 100:253-67. 2007
  47. ncbi request reprint The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertension
    Jan Basile
    Ralph H Johnson VA Medical Center, Charleston, SC, USA
    J Clin Hypertens (Greenwich) 9:636-45. 2007
  48. pmc Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Jackson T Wright
    Department of Medicine, General Clinical Research Center, Cleveland, Ohio, USA
    Arch Intern Med 168:207-17. 2008
    ....
  49. ncbi request reprint The cardiometabolic syndrome and calcium channel blocker combination drugs
    James R Sowers
    Diabetes Research Center, University of Missouri Columbia, Columbia, MO, USA
    J Cardiometab Syndr 2:207-12. 2007
    ..The authors maintained full control of the discussion and the resulting content of this article...
  50. ncbi request reprint Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study
    Henry R Black
    New York University School of Medicine, New York, NY 10016, USA
    J Clin Hypertens (Greenwich) 9:760-9. 2007
    ....
  51. pmc Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial
    Karen L Margolis
    HealthPartners Research Foundation, Box 1524, Mailstop 21111R, Minneapolis, Minnesota 55440 1524, USA
    Hypertension 52:847-55. 2008
    ..01 (95% CI: 0.96 to 1.06.) In postmenopausal women, calcium plus vitamin D3 supplementation did not reduce either blood pressure or the risk of developing hypertension over 7 years of follow-up...
  52. ncbi request reprint Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Linda B Piller
    University of Texas Health Science Center at Houston, School of Public Health, Houston, TX 77030, USA
    J Clin Hypertens (Greenwich) 8:649-56; quiz 657-8. 2006
    ..One patient died following an angioedema episode. The occurrence of angioedema in the angiotensin-converting enzyme inhibitor arm corresponds with previously reported angioedema-angiotensin-converting enzyme inhibitor associations...
  53. pmc Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the chrono trial
    L Michael Prisant
    Medical College of Georgia, Augusta, GA, USA
    J Natl Med Assoc 97:377-83. 2005
    ..In a trial conducted in actual clinical practices, the CODAS formulation of verapamil was shown to be safe and effective in African Americans, Caucasians, Hispanics and Asians...
  54. ncbi request reprint Treatment of elderly hypertensive patients with a delayed-release verapamil formulation in a community-based trial
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
    Am J Geriatr Cardiol 13:131-6. 2004
    ..CODAS verapamil was found to be efficacious and well tolerated among elderly hypertensive patients in this community trial...
  55. ncbi request reprint Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial
    John B Kostis
    Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, One Robert Wood Johnson Place, PO Box 19, New Brunswick, NJ 08903 0019, USA
    Am J Hypertens 17:103-11. 2004
    ..We compared the efficacy and safety of omapatrilat to a representative angiotensin-converting enzyme (ACE) inhibitor, enalapril...
  56. ncbi request reprint Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Aram V Chobanian
    Boston University School of Medicine, Boston, Mass, USA
    Hypertension 42:1206-52. 2003
    ..Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. This report serves as a guide, and the committee continues to recognize that the responsible physician's judgment remains paramount...
  57. ncbi request reprint Estrogen plus progestin and the risk of coronary heart disease
    JoAnn E Manson
    Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 349:523-34. 2003
    ..In this report, we provide the final results with regard to estrogen plus progestin and CHD from the Women's Health Initiative (WHI)...
  58. ncbi request reprint The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    Aram V Chobanian
    Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
    JAMA 289:2560-72. 2003
    ..Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount...
  59. ncbi request reprint Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 8:334-41, 345. 2002
    ..The need to reduce renin-angiotensin aldosterone system activity in a heart failure patient would seem to justify the small risk of angioedema with ARB therapy in a patient having previously experienced ACE inhibitor-related angioedema...
  60. ncbi request reprint Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    William C Cushman
    J Clin Hypertens (Greenwich) 4:393-404. 2002
    ..Achievable control rates in varied practice settings and geographic regions and factors that predict improved blood pressure control are not well identified...
  61. ncbi request reprint Chrono: a community-based hypertension trial of a chronotherapeutic formulation of verapamil
    L Michael Prisant
    Hypertension and Clinical Pharmacology, Medical College of Georgia, Augusta, GA 30912 3105, USA
    Am J Ther 9:476-83. 2002
    ..Upward titration of Verelan PM from 200 to 400 mg nearly doubled the DBP response rate (45.8% to 85.3%). This chronotherapeutic formulation of verapamil was well tolerated in this community trial...
  62. ncbi request reprint Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?
    Domenic A Sica
    Department of Medicine, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 4:375-80. 2002
    ..Such justification might include the presence of heart failure or proteinuric nephropathic states among other considerations...
  63. ncbi request reprint Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial
    John B Kostis
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08903 0019, USA
    Am J Hypertens 15:193-8. 2002
    ..Additional analyses will be conducted in men and women, in diabetic patients, in different risk classes and according to prior evidence of vascular disease...
  64. ncbi request reprint A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 150:401. 2005
    ..We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis...
  65. ncbi request reprint Expanding the definition and classification of hypertension
    Thomas D Giles
    Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 7:505-12. 2005
    ..We believe it would be preferable to classify all individuals as either normal or hypertensive, based on their cardiovascular evaluation, using the four categories of normal and stages 1, 2, and 3 hypertension...
  66. ncbi request reprint ACE inhibitors: over two decades of use
    Domenic A Sica
    Virginia Commonwealth University, Richmond, VA, USA
    J Clin Hypertens (Greenwich) 7:531-7. 2005
    ..Dr. Henry R. Black of Rush University Medical Center, Chicago, IL; and Dr. Vito M. Campese of the University of Southern California, Los Angeles, CA...
  67. ncbi request reprint Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Frans H H Leenen
    University of Ottawa Heart Institute, Ottawa, Ontario, Canada
    Hypertension 48:374-84. 2006
    ..Some, but not all, of these differences may be explained by less effective blood pressure control in the lisinopril arm...
  68. ncbi request reprint Blood pressure reduction is not the only determinant of outcome
    Peter S Sever
    International Centre for Circulatory Health, Imperial College London, 59 N Wharf Rd, London, W2 1PG, UK
    Circulation 113:2754-72; discussion 2773-4. 2006
  69. ncbi request reprint Feasibility of treating prehypertension with an angiotensin-receptor blocker
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
    N Engl J Med 354:1685-97. 2006
    ..Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension...
  70. ncbi request reprint Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events...
  71. ncbi request reprint Calcium plus vitamin D supplementation and the risk of fractures
    Rebecca D Jackson
    Division of Endocrinology, Ohio State University, 485 McCampbell, 1581 Dodd Dr, Columbus, OH 43210, USA
    N Engl J Med 354:669-83. 2006
    ..The efficacy of calcium with vitamin D supplementation for preventing hip and other fractures in healthy postmenopausal women remains equivocal...
  72. ncbi request reprint Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
    Barbara V Howard
    MedStar Research Institute Howard University, Washington, DC, USA
    JAMA 295:655-66. 2006
    ..Multiple epidemiologic studies and some trials have linked diet with cardiovascular disease (CVD) prevention, but long-term intervention data are needed...
  73. ncbi request reprint Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
    Shirley A A Beresford
    Department of Epidemiology, University of Washington, Seattle, WA 98195 7236, USA
    JAMA 295:643-54. 2006
    ..Observational studies and polyp recurrence trials are not conclusive regarding the effects of a low-fat dietary pattern on risk of colorectal cancer, necessitating a primary prevention trial...
  74. ncbi request reprint Commentary on ICEBERG
    Henry R Black
    New York University School of Medicine, New York, NY 10003, USA
    J Clin Hypertens (Greenwich) 9:557. 2007
  75. ncbi request reprint The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions
    Victor J Dzau
    Duke University Medical Center and Health System DUMC 3701, Durham, NC 27710, USA
    Circulation 114:2871-91. 2006
  76. ncbi request reprint The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)
    Victor J Dzau
    Duke University Medical Center and Health System DUMC 3701, Durham, NC 27710, USA
    Circulation 114:2850-70. 2006
  77. ncbi request reprint Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
    Ross L Prentice
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Wash 98109, USA
    JAMA 295:629-42. 2006
    ..The hypothesis that a low-fat dietary pattern can reduce breast cancer risk has existed for decades but has never been tested in a controlled intervention trial...
  78. ncbi request reprint Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Preventi
    Clive Rosendorff
    Veterans Health Administration, USA
    Circulation 115:2761-88. 2007

Research Grants3

  1. MASTERS OF SCIENCE IN CLINICAL RESEARCH
    Henry Black; Fiscal Year: 2004
    ..Their success will be followed yearly by the Program Director of the Clinical Research Curriculum Award ..
  2. Web-Based Project Tracking to Enhance IRB Operations
    Henry Black; Fiscal Year: 2002
    ..e., evaluating proposals for safety, risk, and safeguards; improving the quality of the informed consent process; and educating investigators and research staff about the responsible conduct of research. ..
  3. Web-Based Project Tracking to Enhance IRB Operations
    Henry Black; Fiscal Year: 2003
    ..abstract_text> ..